The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.
The company beat analyst estimates on both the top and bottom lines, with growth reported in its crosslab, diagnostics and genomics, and life sciences and applied market groups.
Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.
The firm's 14 percent growth in molecular diagnostics sales was driven primarily by continued strength across its Aptima women's health products globally.
GenMark placed 65 ePlex analyzers in Q3, the first full quarter after the platform's launch in the US, and it expects to exit 2017 with up to 200 placements.
The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.
The company beat analyst estimates on the top and bottom lines, and said sales from its diagnostics business rose 13 percent year over year.
Excluding revenues from the sale of MDxHealth's colorectal cancer patents to Exact Sciences, total revenues increased approximately 3 percent for the period.
The company, which beat analyst estimates on both the top and bottom lines, said Cologuard test volume in Q3 2017 rose 136 percent year over year.
The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.
The New York City Police Department will be removing DNA profiles from a local database if they are from people who were never convicted of a crime, the New York Times reports.
Science reports that accusations of sexual assault against a microbiome researcher has also led to questions about his academic certifications.
Wired reports that researchers are analyzing the DNA fish leave behind in water to study their populations.
In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.